Condition or Therapy:

Leukemia and lymphoma 


Cancer and Blood Disorders

What is the goal of this study?

PLAT-05 is a first-in-the-nation pediatric phase 1 trial that tests the safety and feasibility of CAR T cells that have been reprogrammed to target CD19 and CD22 proteins simultaneously. CD19 and CD22 are expressed by most leukemia cells. 

Our researchers developed PLAT-05 as an investigational treatment option that will hopefully lead to long-term remission for patients whose cancer expresses CD19 and CD22.

Learn how CAR T-cell therapy works

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are ages 1 to 26 years old
  • Have relapsed or refractory pre-B acute lymphoblastic leukemia (ALL) or other CD19+ or CD22+ acute leukemia or CD19+ non-Hodgkin lymphoma. It is not open to young people with other leukemias or other childhood cancers.

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about the PLAT-05 study on

What other PLAT studies are open for enrollment at Seattle Children's?

  • PLAT-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T-Cell Immunotherapy for CD19+ Leukemia
  • PLAT-03: A Pilot Feasibility and Safety Study of CD19t T-APC Vaccination Following CAR T-Cell Immunotherapy for CD19+ Leukemia
  • PLAT-04: A Phase 1 Feasibility and Safety Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia
  • PLAT-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

Who can I contact for more information?

Please email or call us at 206-987-2106 to learn more about the study.

Study Location(s):

Seattle Children's Hospital main campus 

Principal Investigator:

Dr. Rebecca Gardner